Akribion Therapeutics
Latest round
- Seed
Last raised
- Jan 2025
Total raised
- $8.4M
Investors
- 5
About Akribion Therapeutics
Founded in 2024 in Zwingenberg, Germany, Akribion Therapeutics specializes in RNA-guided enzyme technologies. The founder’s specific background is not detailed, and no mergers, carve-outs, or parent companies have been referenced. Lukas Linning co-founded the firm and led the firm as Co-CEO as of 2025. Akribion Therapeutics utilizes a proprietary G-dase® E payload technology designed for programmable cell depletion. This method selectively targets unwanted cells by matching guide RNA with intracellular RNA, primarily focusing on HPV-induced Oropharyngeal Head & Neck Cancer (OPSCC) while exploring applications in oncology, autoimmune diseases, and infectious diseases. The company aims its services at healthcare providers and research institutions across Europe and North America. Akribion Therapeutics generates revenue through strategic partnerships and licensing agreements related to its G-dase® E technology. Revenue streams may include milestone payments and royalties from product sales, emphasizing B2B transactions with healthcare institutions rather than direct consumer sales.
Who invested in Akribion Therapeutics
5 investors across 1 round
See all investors in Akribion Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Seed
Jan 24, 2025
Amount
$8.4M
Investors
Questions about Akribion Therapeutics
Who invested in Akribion Therapeutics?
Akribion Therapeutics has 5 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Akribion Therapeutics raised?
Akribion Therapeutics has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Akribion Therapeutics last raise money?
Akribion Therapeutics's most recent round on record is a Seed, in Jan 2025.
What does Akribion Therapeutics do?
Founded in 2024 in Zwingenberg, Germany, Akribion Therapeutics specializes in RNA-guided enzyme technologies.
Where is Akribion Therapeutics headquartered?
Akribion Therapeutics is headquartered in Zwingenberg, Germany.
Which VCs invest in companies like Akribion Therapeutics?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Balderton Capital back biotechnology companies at Akribion Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Seed
Raising like Akribion Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.